Anzeige
Mehr »
Donnerstag, 25.12.2025 - Börsentäglich über 12.000 News
Prof. Dr. Dr. Andreas Pfützner: Geniale Lösung für Diabetiker!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von The Motley Fool Australia

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
Mo$5,000 to spare? I'd buy these 3 ASX 200 shares before the end of 2025
MoWhy Domino's Pizza Enterprises, HMC Capital, Regis Healthcare, and WiseTech shares are falling today
MoUp 162% in 6 months! Expert tips this surging ASX lithium stock to double again
MoWhy is this ASX rare earths stock rocketing 36% today?
MoIs it too late to buy surging ASX lithium shares like Mineral Resources and Liontown?
MoWhy is everyone talking about DroneShield shares today?
MoIf you'd invested $1,000 in Apple 10 years ago, here's how much you'd have today
MoLendlease unveils $400m TRX sale and FY26 capital recycling update
MoReece announces $85 million on-market buyback target
MoUp 130% in a year, ASX All Ords gold stock lifts off on 'valuable gold price protection' news
MoRegis Healthcare CEO resignation: Leadership transition update
MoTelix shares storm higher on big US and China news
MoClinical trial of potential diabetes and arthritis treatment delivers positive results
MoBell Potter names three engineering companies to buy
MoThe best artificial intelligence stock to buy in 2026
MoThis ASX AI stock is jumping 9% on huge news
MoAurizon lodges new 10-year network access undertaking with QCA
MoThese are the 10 most shorted ASX shares
SoStockland announces estimated 1H26 distribution
SoAll systems go for BlueScope Steel shares
SoChampion Iron launches $289m Rana Gruber takeover: what shareholders need to know
SoWhat's next on the horizon for EOS? Why I think 2026 could be massive
SoNEXTDC lifts contracted utilisation and order book in December update
SoAre Boss Energy shares a cheap buy after crashing 50%?
SoTelix Pharmaceuticals in focus with China trial success and FDA updates